Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
Allarity Therapeutics announced the presentation of two scientific posters at AACR 2026, showcasing stenoparib's dual PARP and WNT pathway inhibition in colorectal cancer and its companion diagnostic (DRP®) linked to improved overall survival in ovarian cancer patients. These data underline the drug’s potential as a novel cancer therapeutic and the…